A B S T R A C T We have tested the beta adrenergic receptor theory of bronchial asthma by determining the number and affinity of binding sites of the beta adrenergic radioligand [3H]dihydroalprenolol (DHA) and the activity ofadenylate cyclase in broken cell preparations of polymorphonuclear leukocytes (PMN). We studied 31 control subjects (group 1), 30 asthmatics receiving no systemic adrenergic medication (group 2), and 17 asthmatics receiving adrenergic agonists systemically (group 3). Control subjects and asthmatics taking no adrenergic drugs bound similar amounts of DHA at 0.5 nM and 30 nM DHA and had about 900 binding sites per PMN. In contrast, asthmatics receiving adrenergic agonists had a >70% decrease in their number of DHA binding sites per PMN (254+±57). In a subset of our three groups of subjects (eight from group 1, six from group 2, and five from group 3) we measured DHA binding at several DHA concentrations and found similar values (0.4-0.7 nM) for the dissociation constant of DHA among these subjects.
INTRODUCTION
In 1968, Szentivanyi (1) postulated that the underlying defect in atopic diseases, particularly bronchial asthma, is an imbalance of the autonomic nervous system. He suggested that beta adrenergic receptor function is decreased in asthmatic patients and that this results in increased alpha adrenergic and cholinergic responses to a variety of stimuli. Certain evidence has been reported that appears to confirm the possibility of beta adrenergic blockade in pulmonary (2, 3) and extrapulmonary tissues in asthmatics (4) . A consequence of this blockade would be decreased cellular cyclic AMP, which in the lung would promote bronchospasm and mediator release (5, 6) . Because it is difficult to study samples of lung in human subjects, several investigators have used either peripheral blood leukocytes or lymphocytes to show that asthmatics have decreased stimulation of cyclic AMP by beta adrenergic agonists (7, 8) . Two problems must be considered in assessing these studies: (a) beta adrenergic responses and receptors in T and B lymphocytes may be quite different (9, 10) , and thus changes in adrenergic response in asthmatics might reflect altered distribution of cells in lymphocyte subpopulations; and (b) prior administration of beta adrenergic agonists reportedly diminishes subsequent beta adrenergic stimulation of leukocyte cyclic AMP (11) (12) (13) . Thus, changes in responsiveness of asthmatics might arise from therapy as well as from the disease itself. Some authors (7) have attempted to consider these problems in studies with lymphocytes.
Neutrophilic polymorphonuclear cells (PMN)1 may be more suitable than lymphocytes for clinical studies of beta adrenergic receptors, because PMN appear to be a more homogeneous population than are lymphocytes. In addition, PMN have well-defined beta adrenergic responses that have been reported to be decreased in asthmatics (14) (15) (16) . Recently we have used [3H]dihydroalprenolol (DHA), a radiolabeled beta adrenergic antagonist to characterize beta adrenergic binding sites (i.e., receptors) on PMN particulates prepared from normal subjects (17) . In this study we have compared DHA binding of control subjects with binding of asthmatics who either were or were not receiving adrenergic agents. In addition, we have compared the ability of the agonist isoproterenol to compete for DHA binding sites and to stimulate adenylate cyclase in broken PMN from controls and asthmatics. We find that asthmatics have only minimal alterations in PMN beta adrenergic receptors unless the patients are receiving therapy with beta adrenergic agonists. (Table II) . There were nine males and eight females with an age range of 18 to 60 (mean age, 35 yr). The duration of asthma ranged from 1 to 58 yr (mean, 17 yr).
METHODS

Subjects
Selection of criteria
The subjects in all three groups were carefully screened to exclude individuals with active viral infections, those receiving birth control medication, cardiac glycosides, antihypertensive agents, or other sympathomimetic containing medication. All asthmatics in this study had previously demonstrated reversible airway disease by pulmonary function testing.
Grading of asthma severity and activity Severity of disease was graded on the basis of the overall course of asthma with the following criteria: (a) steroid usage, (b) requirement for bronchodilation therapy to control asthma, (c) frequency and persistence of asthma exacerbations, and (d) hospitalization. From these criteria asthmatics were identified as mild, moderate, or severe. Mild asthmatics could be controlled with intermittent bronchodilator therapy. Patients in the moderate category required daily bronchodilator therapy and short courses of steroids for acute exacerbations. The severe asthmatics required frequent treatment (more than one course per month) with steroids, daily bronchodilators, and had persistent wheezing with frequent exacerbations ofasthma often requiring hospitalization. The activity of disease was scored as 0 to 3, where 0 meant that no wheezing had occurred within 3 mo, 1 indicated wheezing between 14 d and 3 mo, 2 signified wheezing within 2 wk, and 3 indicated acute asthma at the time of the study.
Preparation of PMN particulates 60 ml of heparinized blood was obtained from each subject in the study. Patients on adrenergic therapy were sampled generally 2-4 h after taking their medication. Blood was centrifuged on a Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, N. J.) density gradient according to the method of Boyum (18) . Particulates from PMN (90±3.5% SD of final cells obtained) were prepared as described (17) Beta adrenergic receptor assay DHA Binding assays contained in a total volume of 0.15 ml: DHA, PMN membranes (-0.440 mg protein in which 1 mg protein corresponds to 1.7 x 107 cells), 50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM ascorbic acid, 0.3 mM catechol, and 0.1 mM phentolamine. Ascorbic acid was included to block oxidation of catecholamines, and catechol and phentolamine were added to inhibit nonspecific binding (17) . These agents did not affect specific binding. Samples were incubated at 37°C for 15 min. Incubations were terminated by rapidly diluting samples with 2 ml of ice-cold incubation buffer and then immediately filtering the mixture through a glass fiber filter (Gelman A/E, Gelman Instruments Co., Ann Arbor, Mich.). The filters were presoaked in incubation buffer containing 0.1 mM (±)-propranolol to block nonspecific binding of radioactivity to the filters. The filters were rapidly (10 s) washed with 15 ml of ice-cold incubation buffer and the radioactivity bound radioactivity was corrected for counts of 32P retained In this study, adenylate cyclase assays were performed con-on the filters (generally <100 cpm). For samples in which currently with DHA binding studies under identical condi-adenylate cyclase activity was measured, 0.15 ml of 0.33 N tions. Samples were incubated in a total volume of0.17 ml con-HCl was added and cyclic AMP was then isolated by sequen- In studies of receptor affinity we performed DHA binding experiments in eight control subjects, six asthmatics receiving no adrenergic medication (subjects 17-22, Table I ), and 5 asthmatics receiving adrenergic agonists (subjects 13-17, Table II ). Mean data for these three groups are shown in Fig. 1 . Specific binding was saturated and could be resolved into one class of binding sites (r by least squares fit = 0.94, 0.99, and 0.96 for groups 1, 2, and 3, respectively) on Scatchard analysis (Fig. 1, inset) . The mean data shown in Fig. 1 yield a dissociation constant for DHA of 0.39, 0.30, and 0.49 nM for groups 1, 2, and 3, respectively. When individual studies on the 19 subjects were analyzed by Scatchard plots (all r values for regression lines were -0.80) and the individual dissociation constants pooled for the three groups, the population values were 0.41±0.05, 0.38±0.06, and 0.72+0.22 nM (mean±SEM). The values for the dissociation constant for the subjects in group 3 were not statistically different when compared to those for subjects in group 1 or 2 (P > 0.05). These values for the dissociation constant for DHA are somewhat lower than we reported previously (1-5 nM [17] ) and may reflect the fact that the data in Fig. 1 was obtained using sonicates rather than with mem- brane particulates, which were used in our earlier study and in the studies shown in Fig. 2 .
Data for maximal number of DHA binding sites in these subjects were obtained in two ways: (a) Scatchard analysis of data for the subjects depicted in Fig. 1 and (b) DHA binding determined in a larger group of 26 controls, 22 subjects in grouip 2 (subjects , and 17 subjects in group 3 at a single concentration of DHA (30 nM) . This concentration appears to be close to saturating for these three groups of subjects ( Fig. 1 and [17] As an additional experiment to determine ifa population of asthmatic subjects might have differences in binding of DHA, we measured binding at 0.5 nM DHA in the same 26 control subjects, 22 subjects in group 2, and 17 subjects in group 3 in whom we measured binding at 30 nM DHA (Fig. 2, left panel) . Again, subjects in group 1 and 2 showed nearly identical amounts of DHA binding, whereas subjects in group 3 bound significantly (P < 0.01) less DHA than those in either of the two other groups.
Although the data presented thus far indicated insignificant differences for binding of the beta adrenergic antagonist DHA in control subjects and asthmatics not receiving adrenergic therapy, it was important to determine if asthmatics might show an altered affinity for a beta adrenergic agonist. We compared 8 asthmatics from group 2 (subjects 23-30) and 10 control subjects (Fig. 3A) . Competition for DHA bindings sites by the beta adrenergic agonist (-)-isoproterenol was virtually identical in controls and asthmatics. The dissociation constant for isoproterenol calculated from the results for individual studies of the subjects presented in Fig. 3 was 1 .06+0.20 uM for control and 1.00+0.20 ,M for the asthmatic subjects. Adenylate cyclase studies. As a further measure of changes in beta adrenergic receptors in asthma, we also determined basal and isoproterenol-stimulated adenylate cyclase activity in sonicates prepared from PMN and measured under conditions identical to those used to measure competition of (-)-isoproterenol for DHA binding sites (Fig. 3B) . When plotted as percent maximal adenylate cyclase activity, the curves are similar for the two groups, and the Kact for (-)-isoproterenol calculated to be 0.16±0.03 for control and 0.19±0.02 for asthmatic subjects (P > 0.1). Although the absolute activity of basal adenylate cyclase (Fig. 4) is lower in control than in asthmatic subjects (42.0±4.9 vs. 53.5 ±6.8 pmol cAMP generated/min per mg, this difference is not statistically significant [P > 0.1]) and both groups of subjects show about a threefold maximal increase in adenylate cyclase activity in response to isoproterenol and similar responses at each concentration tested. By comparison, the only subject from group 3 (subject 14) whom we tested had a lower basal activity and a blunted response to isoproterenol. DISCUSSION These data indicate that patients with bronchial asthma who are not receiving systemic therapy with adrenergic (22) (23) (24) (25) (26) . Our data offer further evidence that systemic treatment of patients with beta adrenergic agonists appears to "down regulate" receptors for beta adrenergic amines (27) . We have recently shown that asthmatics with moderate to severe asthma, comparable to group 3 in this study, have normal binding 1 wk after adrenergic therapy is discontinued (27) . This would suggest that it is the adrenergic therapy rather than the severity or duration of asthma, which accounts for the decreased beta adrenergic binding in the asthmatics in group 3 compared to those in group 2 with milder asthma or compared to the control population. Because we have found that asthma in patients withdrawn from adrenergic medication worsened, we did not feel justified in repeating this maneuver with the present subjects (27) .
Therefore, because we did not withdraw therapy from subjects in group 3 and because our subjects in group 3 were more ill than those in group 2 and were receiving additional medication (e.g., 0 of 17 subjects in group 3 but 11 of 30 subjects in group 2 received no medication for their asthma), we cannot state unequivocally that therapy with catecholamine agonists, rather than disease severity, is exclusively responsible for the decreased binding in the subjects in group 3. Furthermore, although our findings indicate that treatment with corticosteroids produced no significant increase in the number of beta adrenergic receptors in the asthmatic patients receiving adrenergic agonists, the number of subjects examined was small. More complete studies involving treatment and withdrawal of corticosteroids from normals and asthmatics will be required to ascertain whether such treatment alters properties ofbeta adrenergic receptors in granulocytes.
It is difficult to be certain that our findings for beta adrenergic receptors in PMN derived from asthmatics necessarily reflect the status of receptors from other tissues involved in the pathophysiology of asthma. However, Conolly and Greenacre (28) In an earlier study, Sokol and Beall (29) reported that asthmatics and control subjects had similar numbers of beta adrenergic receptors. In that study the authors identified beta adrenergic receptors by using [3H]epinephrine, a method that was later shown to predominantly represent interaction of oxidized catecholamine derivatives with tissue macromolecules (23) . Thus, our results offer more definitive evidence of the similarity of beta adrenergic receptor number in asthmatics and controls.
In addition our results indicate that beta adrenergic receptor affinity and function (i.e., activation of adenylate cyclase) are similar in PMN from asthmatic and control subjects. In this regard, we should note the relationship between the Kd isoproterenol and Kact isoproterenol in our subjects. We find that the agonist is more potent in activating adenylate cyclase than in competing with DHA for the receptors. It has been proposed that if binding to receptors and activation of adenylate cyclase are examined under identical conNetitrophil Beta Acirenergic Receptors in Asthmna )k ditions, the relationship between Kd and Kact offers an index of the efficiency of coupling between beta adrenergic receptors and adenylate cyclase (23) . We therefore attempted to perform these two assays concurrently with the same conditions. Our findings indicate that beta adrenergic receptors in the PMN membrane are coupled with high efficiency to adenylate cyclase with a Kd/Kact in control subjects of 6.6 and in asthmatics not receiving systemic adrenergic medication of 5.3. These values for PMN particulates are much higher than has been observed for most other tissues with beta adrenergic receptor coupled adenylate cyclase, and are similar to values observed for S49 lymphoma cells, a model system demonstrating highly efficient coupling (23, 30 ). An alternative way of interpreting the relationship between Kd and Kact in PMN is the presence of spare receptors such that only a small fraction of receptors need to be occupied to produce full response.
Our data on asthmatic subjects conflict with two recent reports (31, 32) , which showed that lymphocytes from asthmatics have decreased DHA binding even in the absence of adrenergic therapy. Additionally, our finding of statistically insignificant changes in number of PMN beta adrenergic receptor with increasing age contradict the findings of Schocken and Roth (33) who observed a decrease in number of DHA binding sites on lymphocytes as a function of increasing age. Because recent evidence indicating differences in beta adrenergic receptors in lymphocyte subpopulations (10) , it is possible that the data in lymphocytes may be explained by differences in distribution of lymphocyte subclasses in asthmatics and older people. Alternatively, we have to consider the possibility that data obtained with PMN may not necessarily apply to other beta adrenergic receptors in the body.
The preliminary findings recently reported by Sano et al. (34) suggest that this theoretical possibility may, in fact, apply. Using a different radioligand ([1251]iodohydroxybenzylpindolol), Sano et al. found results identical to ours in granulocytes but noted that lymphocytes showed a decrease in number of beta adrenergic receptors even in asthmatics who did not receive adrenergic agonists. More complete characteriztion of beta adrenergic receptors in other tissues will be necessary to determine the validity of results obtained using various types of blood cells.
With respect to asthma and PMN, Busse and Sosman (35) have reported that intact PMN from asthmatic subjects who have been withdrawn from adrenergic therapy for at least 2 wk have decreased histamine and isoproterenol-stimulated cyclic AMP accumulation (16, 35) . Busse and Sosman's results thus indicate that PMN are altered in asthma independent of adrenergic therapy. In reconciling Busse and Sosman's findings and other reports in the literature with those in this study, we suggest that if beta adrenergic hyporesponsiveness occurs in intact leukocytes from patients with bronchial asthma, this decreased response is not attributable to defective beta adrenergic receptor binding as detected in disrupted PMN. In light of recent evidence indicating differences in properties of beta adrenergic receptors in intact and broken cells (30, 36, 37) , it may prove fruitful to perform more detailed studies comparing adrenergic receptors and adrenergic response in intact PMN prepared from asthmatic and control subjects.
